MoonLake Immunotherapeutics
MLTX
$55.65
$0.811.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.94M | 11.03M | 9.22M | 7.38M | 6.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.70M | 47.49M | 49.58M | 43.11M | 30.58M |
| Operating Income | -60.70M | -47.49M | -49.58M | -43.11M | -30.58M |
| Income Before Tax | -55.96M | -40.41M | -46.35M | -36.02M | -24.68M |
| Income Tax Expenses | 95.00K | 153.00K | 41.10K | 92.10K | 79.00K |
| Earnings from Continuing Operations | -56.05M | -40.56M | -46.40M | -36.11M | -24.76M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 831.00K | 615.00K | 791.20K | 724.10K | 492.00K |
| Net Income | -55.22M | -39.94M | -45.60M | -35.39M | -24.27M |
| EBIT | -60.70M | -47.49M | -49.58M | -43.11M | -30.58M |
| EBITDA | -59.96M | -47.11M | -48.28M | -43.08M | -30.24M |
| EPS Basic | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 |
| Normalized Basic EPS | -0.54 | -0.39 | -0.45 | -0.35 | -0.24 |
| EPS Diluted | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 |
| Normalized Diluted EPS | -0.54 | -0.39 | -0.45 | -0.35 | -0.24 |
| Average Basic Shares Outstanding | 63.28M | 63.23M | 63.07M | 62.90M | 62.87M |
| Average Diluted Shares Outstanding | 63.28M | 63.23M | 63.07M | 62.90M | 62.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |